Title: A Prospective study to assess Prognostic factors for patients with Cervical cancer stage II treated with concurrent chemoradiotherapy
Authors: Dr Rahul Kumar Rai, Dr Rajesh Kumar, Dr Neeti Sharma , Dr Neha Rawat, Dr Narendra Kumar Gupta, Dr H S Kumar
Background: Concurrent chemoradiotherapy is standard of care for the management of cervical cancer.
Objective: In this study we try to explore various prognostic factors for management of cervical cancer, stage II. The main objective was to analyze impact of various factors on disease response and toxicities.
Methods: This is a prospective analysis of 50 patients of stage II cervical cancer, treated with concurrent chemoradiotherapy. The most common regime used was Concurrent EBRT (External Beam Radiotherapy) + HDR (High Dose Rate) ICBT (Intra cavitary Brachytherapy) + weekly cisplatin (40 mg/m2). The most common dose fractionation regime was 7.5 Gy X 3 fractions or 6 Gy X 4 fractions. A total dose of 50 Gy was delivered by EBRT.
Results: Of the 50 patients, 14 patients (28%) were in stage IIa while 36 (72%) were in stage IIb. 41 (82%) achieved CR.
Conclusion: Out of the various factors analyzed NLR (Neutrophil-Leucocyte Ratio), pre-treatment Hb (Hemoglobin) value, number of weekly cisplatin cycle received were the only factors with significant impact on prognosis.
Keywords: Cervical cancer, HDR intracavitary brachytherapy, Prognostic factors, dose fractionation, acute toxicity, late toxicity.